Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer

Wei Chua; Patricia S. Kho; Melissa M. Moore; Kellie A. Charles; Stephen J. Clarke

doi:10.1016/j.critrevonc.2010.07.012

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer

Wei Chua, Patricia S. Kho, Melissa M. Moore, Kellie A. Charles, Stephen J. Clarke

Western Sydney University

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

Colorectal cancer (CRC) treatment has evolved significantly over the last ten years with the use of active chemotherapeutic agents including fluoropyrimidines, oxaliplatin and irinotecan plus targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab. The addition of newer chemotherapeutic agents and targeted therapies has improved patient outcomes at the cost of increased toxicity with not all patients benefiting from these treatments. It is necessary for clinicians to more accurately predict clinical outcomes particularly in the predominantly elderly CRC patient population. This review aims to summarise existing data regarding the use of clinical and laboratory variables plus molecular markers in predicting response, survival and toxicity to chemotherapy agents and targeted monoclonal antibodies currently used in the treatment of CRC.

Original language	English
Pages (from-to)	224-250
Number of pages	27
Journal	Critical Reviews in Oncology/Hematology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1016/j.critrevonc.2010.07.012
Publication status	Published - 2011

Keywords

biochemical markers
cancer
chemotherapy
colon (anatomy)
monoclonal antibodies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.critrevonc.2010.07.012

Cite this

@article{b5465b91c7ee441ea2417c1ade5b0d0c,

title = "Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer",

abstract = "Colorectal cancer (CRC) treatment has evolved significantly over the last ten years with the use of active chemotherapeutic agents including fluoropyrimidines, oxaliplatin and irinotecan plus targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab. The addition of newer chemotherapeutic agents and targeted therapies has improved patient outcomes at the cost of increased toxicity with not all patients benefiting from these treatments. It is necessary for clinicians to more accurately predict clinical outcomes particularly in the predominantly elderly CRC patient population. This review aims to summarise existing data regarding the use of clinical and laboratory variables plus molecular markers in predicting response, survival and toxicity to chemotherapy agents and targeted monoclonal antibodies currently used in the treatment of CRC.",

keywords = "biochemical markers, cancer, chemotherapy, colon (anatomy), monoclonal antibodies",

author = "Wei Chua and Kho, {Patricia S.} and Moore, {Melissa M.} and Charles, {Kellie A.} and Clarke, {Stephen J.}",

year = "2011",

doi = "10.1016/j.critrevonc.2010.07.012",

language = "English",

volume = "79",

pages = "224--250",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland ",

number = "3",

}

TY - JOUR

T1 - Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer

AU - Chua, Wei

AU - Kho, Patricia S.

AU - Moore, Melissa M.

AU - Charles, Kellie A.

AU - Clarke, Stephen J.

PY - 2011

Y1 - 2011

N2 - Colorectal cancer (CRC) treatment has evolved significantly over the last ten years with the use of active chemotherapeutic agents including fluoropyrimidines, oxaliplatin and irinotecan plus targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab. The addition of newer chemotherapeutic agents and targeted therapies has improved patient outcomes at the cost of increased toxicity with not all patients benefiting from these treatments. It is necessary for clinicians to more accurately predict clinical outcomes particularly in the predominantly elderly CRC patient population. This review aims to summarise existing data regarding the use of clinical and laboratory variables plus molecular markers in predicting response, survival and toxicity to chemotherapy agents and targeted monoclonal antibodies currently used in the treatment of CRC.

AB - Colorectal cancer (CRC) treatment has evolved significantly over the last ten years with the use of active chemotherapeutic agents including fluoropyrimidines, oxaliplatin and irinotecan plus targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab. The addition of newer chemotherapeutic agents and targeted therapies has improved patient outcomes at the cost of increased toxicity with not all patients benefiting from these treatments. It is necessary for clinicians to more accurately predict clinical outcomes particularly in the predominantly elderly CRC patient population. This review aims to summarise existing data regarding the use of clinical and laboratory variables plus molecular markers in predicting response, survival and toxicity to chemotherapy agents and targeted monoclonal antibodies currently used in the treatment of CRC.

KW - biochemical markers

KW - cancer

KW - chemotherapy

KW - colon (anatomy)

KW - monoclonal antibodies

UR - https://hdl.handle.net/1959.7/uws:56049

U2 - 10.1016/j.critrevonc.2010.07.012

DO - 10.1016/j.critrevonc.2010.07.012

M3 - Article

SN - 1040-8428

VL - 79

SP - 224

EP - 250

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 3

ER -

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this